Short Interest in GT Biopharma, Inc. (NASDAQ:GTBP) Expands By 23.4%

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 13,700 shares, a growth of 23.4% from the November 30th total of 11,100 shares. Approximately 0.7% of the shares of the stock are sold short. Based on an average daily volume of 355,500 shares, the short-interest ratio is presently 0.0 days.

GT Biopharma Price Performance

Shares of GTBP traded up $0.01 during mid-day trading on Tuesday, reaching $3.06. The company’s stock had a trading volume of 29,343 shares, compared to its average volume of 447,347. The business has a fifty day moving average of $2.89 and a 200 day moving average of $2.58. GT Biopharma has a 1 year low of $1.72 and a 1 year high of $10.66.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on GTBP shares. Roth Capital raised GT Biopharma to a “strong-buy” rating in a research note on Monday, December 2nd. Roth Mkm started coverage on shares of GT Biopharma in a research note on Monday, December 2nd. They set a “buy” rating and a $11.00 price objective for the company.

GT Biopharma Company Profile

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.